5^th World Hematologists Congress

The increased life expectancy of persons with bleeding disorders (PBD), presently in general over 70 years in the developed world achieved through the improved factor replacement therapy leads to the novel medical challenges. Several pathologic conditions including cardiovascular disease, atherosclerosis and subsequent thromboembolic events are clearly associated with aging in the general population. Limited but growing evidence shows that the aging sub-population of PBD is affected to some extend depending on the severity of the disease and concomitant prothrombotic risk factors including inherited thrombophilia by the increased risk of thromboembolic events particularly those related to atherosclerosis as well. The risk is prominent in the sub-group with mild to moderate severity of the bleeding disorder and might be increased in those affected by clinically relevant thrombophilia. The thrombotic events in PBD represent therapeutic challenge, since the application of the standard

therapeutic approach; the prolonged administration of antithrombotics requires establishing a balance between antithrombotic and antihemorrhagic treatment. Furthermore, evidence-based data are presently limited and thus the individualized approach has to be usually applied. The aim of the work is to demonstrate the author's own experience with the diagnostics and treatment

of thrombotic events in PBD and to summarize the known data on the problem. The dominant focus should be on inherited hemophilias.